Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30573% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Platform research R&D by Quarter
Platform research R&D (FY2018–FY2023 disaggregation) ($M) ($M)
Moderna Platform research R&D: $32M in Q3 2022, up 14.3% from a year earlier. No newer figure appears in the documents we track.
Latest, Q3 2022
32
Period ended Sep 30, 2022
Change on a year earlier
+14.3%
28 in Q3 2021
History
8 quarters
Since Q1 2019
Sources
5
Documents cited below
Where the Q3 2022 figure comes from
“Platform research | 32 | 28 | 97 | 80”
Source: Q3 2022 10-Q ↗
Reported in Form 10-K / 10-Q Item 7 (MD&A R&D Breakdown).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Platform research R&D (FY2018–FY2023 disaggregation) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2022 | Sep 30, 2022 | 32 | +14.3% | Q3 2022 10-Q ↗ |
| Q2 2022 | Jun 30, 2022 | 31 | +14.8% | Q2 2022 10-Q ↗ |
| Q1 2022 | Mar 31, 2022 | 34 | +36.0% | Q1 2022 10-Q ↗ |
| Q3 2021 | Sep 30, 2021 | 28 | – | Q3 2022 10-Q ↗ |
| Q2 2021 | Jun 30, 2021 | 27 | – | Q2 2022 10-Q ↗ |
| Q1 2021 | Mar 31, 2021 | 25 | +13.6% | Q1 2022 10-Q ↗ |
| Q1 2020 | Mar 31, 2020 | 22 | -10.2% | Q1 2021 10-Q ↗ |
| Q1 2019 | Mar 31, 2019 | 24.5 | – | Q1 2020 10-Q ↗ |
Cite this data
StockData. (2026). Moderna Platform research R&D ($M), quarterly Q1 2019–Q3 2022 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/rd-platform-research-leg
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.